back to search abstracts online
Abstract 1. Comparison between IFA and EIA Assays in Detecting Seroconversion to Human Herpesvirus 8 (HHV-8) in Persons Identified with Human Immunodeficiency Virus (HIV)
Abstract 2. Seroepidemiology of Human Herpesvirus 8 among Young Men Who Have Sex with Men
Abstract 3. Induction of HHV-8 Lytic Cycle Replication by Cytokines Produced by HIV-1-Infected T-Cells
Abstract 4. Human Herpesvirus 8 Open Reading Frame K1 Signals through NFkB and Activates Cells
Abstract 4A. Quantitative Analysis of KSHV (HHV-8) Virus Load in Plasma, PBMC and Lymph Nodes from HIV-1-Infected Persons
Abstract 5. Interleukin 12 (IL-12) Appears to Be Active in AIDS-Associated Kaposi's Sarcoma (KS): Early Results of a Pilot Study
Abstract 6. HIV Implicated in the cis-Activation of c-fes in a Subset of HIV-Associated Lymphomas
Abstract 7. c-fes Proto-Oncogene Expression in HIV and Non-HIV Lymphoid Tissues
Abstract 8. HIV Status and Anal Human Papillomavirus Infection in Adolescents
Abstract 9. Incidence of Cancer in Women with or at Risk for HIV
Abstract 10. Spectrum of AIDS-Associated Malignancies in New York City
Abstract 11. Cancer Incidence among HIV-Infected Men and Women in Southern Europe
Abstract 12. Incidence of Lipodystrophy in Patients with Primary HIV-1 Infection (PHI) Treated with HAART
Abstract 13. Prevalence of Metabolic Complications in a Large Diverse Cohort of HIV-Infected Persons
Abstract 14. Factors Related to the Presence of Fat Redistribution in HIV-Infected Patients Treated With Protease Inhibitor (PI)-Containing Regimens, APROCO Cohort, 1999
Abstract 15. Risk Factors for Developing Lipodystrophy (LD) in Patients Receiving Protease Inhibitors (PI)
Abstract 16. Incidence, Characteristics, and Prognosis of Diabetes Mellitus (DM) Associated with Proease Inhibitors (PI)
Abstract 17. Lipodystrophy and Metabolic Disorders in 646 HIV-1 Infected Patients Previously Treated with or without a Protease Inhibitor (PI)
Abstract 18. Fat Distribution and Retinoid-like Symptoms Are Infrequent in NRTI-Experienced Subjects Treated with Amprenavir
Abstract 19. Prevalence of Lipodystrophy in the Long-Term Follow-up of a Clinical Trial Comparing Various Combinations of Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTI), ALBI Trial (ANRS 070)
Abstract 20. Lipodystrophy in PI-naive Patients Treated with RTI Combinations: Frequency and Risk Factors
Abstract 21. Influence of Thymidine Analogues and NNRTI Choice on Cholesterol Levels during Antiretroviral Therapy
Abstract 22. Comparison of Abdominal Fat Distribution in HIV+ Patients, with and without Clinical Fat Redistribution and HIV- Patients, Using Computed Tomography (CT)
Abstract 23. Clinical Factors Related to the Severity of Fat Redistribution in the HIV Outpatient Study (HOPS)
Abstract 24. Prevalence of Fat Deposition and Fat Atrophy in a Cohort of HIV-Infected Men and Women
Abstract 25. Body Habitus Assessments in HIV-Infected Women: A Cross-Sectional Study
Abstract 26. Gender Differences in HIV-Associated Adipose Redistribution Syndrome (HARS): An Update
Abstract 27. Gender Differences in Prevalence of Body Habitus Changes and Metabolic Complications in HIV + African American and Latino Individuals from Harlem
Abstract 28. Cumulative Time-Dependent Probability of Developing Fat Tissue Alterations in Female Patients Treated with Combined Antiretroviral Therapy
Abstract 29. Endothelial Dysfunction Is Associated with the Use of Human Immunodeficiency Virus-1 Protease Inhibitors
Abstract 30. Noninvasive Morphological Analysis of Carotid and Femoral Arteries in Protease-Inhibitor-Treated HIV-Infected Individuals
Abstract 31. Diagnosis and Determinants of Subclinical Arterial Disease in HIV1-Infected Patients on HAART
Abstract 32. A Pilot Study of Carotid Intima Media Thickness (IMT) in HIV-Infected Women Treated with Protease Inhibitors
Abstract 33. Do Protease Inhibitors Increase the Risk for Coronary Heart Disease among HIV-Positive Patients? Additional Follow-Up
Abstract 34. Myocardial Infarction Incidence in Clinical Trials of 4 Protease Inhibitors
Abstract 35. Detection of Myocardial Ischemia in Protease Inhibitor (PI)-Treated HIV-Infected Patients with Hyperlipemia
Abstract 36. Hypertension (HTN) in HIV Patients with Metabolic Dysregulation
Abstract 37. High Fat Diet and Susceptibility to Obesity Increase the Effects of HIV Protease Inhibitors on Metabolism in Mice
Abstract 38. Positive Correlation between Indinavir and Retinoic Acid Effects in Mice
Abstract 39. Nelfinavir and Ritonavir Stimulate Triglyceride Production in Hepatic Cells
Abstract 40. Differential Effects of Saquinavir on Glucose Transport in a Variety of Cell Cultures
Abstract 41. Efavirenz Increases Dyslipidemia and Hepatomegaly, and Alters Gene Expression in Adipose Tissue of Mice
Abstract 42. Mitochondrial Fat Oxidation Is Not Reduced in HIV-Associated Dyslipidaemia
Abstract 43. Leptin and Soluble Leptin Receptor Levels in Patients with Abnormal Fat Redistribution and Metabolic Disturbances Associated with HIV Therapy
Abstract 44. Why Some Fat Depots Waste but Others Expand in Patients Using Protease Inhibitors: Hypothesis and Supporting Data
Abstract 45. A Prospective Open Label Pilot Trial of a Maintenance Nevirapine (NVP)-Containing Regimen in Patients with Undetectable Viral Loads (VL) on Protease Inhibitor (PI) Regimens for at Least 6 Months
Abstract 46. Identification of Fat Redistribution / Metabolic Anomalies in a Cohort Treated by 2 NRTIs + 1 PI, and Absence of Significant Modification Following PI-Substitution
Abstract 47. Improvement of Lipodystrophy in HIV-1 Infected Subjects Switching from 2NRTI/PI to 2NRTI/Abacavir (French Substudy, CNA30017)
Abstract 48. Partial Improvement of Lipodystrophy after Switching from HIV-1 Protease Inhibitors (PI) to Efavirenz (EFV)
Abstract 49. Evolution of Lipodystrophy Syndrome and Lipidic Profile in HIV Patients after Switching from Protease Inhibitors to Efavirenz
Abstract 50. Impact of Switching from HIV-1 Protease Inhibitors (PI) to Efavirenz (EFV) in Patients with Lipodystrophy
Abstract 51. A Novel Use of Abacavir to Simplify Therapy in PI Experienced Patients Successfully Treated with HAART: CNA30017
Abstract 52. Reversibility of Peripheral Fat Wasting (Lipoatrophy) on Stopping Stavudine Therapy
Abstract 53. Metabolic and Morphologic Effects of Benfluorex in 25 HIV-Infected Patients with Lipodystrophy
Abstract 54. Resistance Exercise Training Reduces Hypertriglyceridemia in HIV-Infected Men Treated with Antiviral Therapy
Abstract 55. Differences in Anion Gap with Different Nucleoside RTI Combinations
Abstract 56. Hyperlactatemia in 20 Patients Receiving NRTI Combination Regimens
Abstract 57. Hyperlactatemia and Antiretroviral Therapy in the Swiss HIV Cohort Study (SHCS)
Abstract 58. Near-Fatal Metabolic Acidosis, Liver Failure in Mitochondrial (mt) DNA Depletion in an HIV-Infected Child Treated with Combination Antiretroviral Therapy (ART)
Abstract 59. Four Cases of Fatal Lactic Acidosis Due to Mitochondrial Toxicity of NRTI Treatment: Analysis of Clinical Features and Risk Factors
Abstract 60. Hypersensitivity Reactions during Therapy with Abacavir: Analysis of 636 Cases for Clinical Presentation and Risk Factors
Abstract 61. Sulfa-Associated Rash and Race are Risk Factors for Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Associated Rash
Abstract 62. Characterization of Nelfinavir (NFV)-Associated Diarrhea: Secretory Versus Osmotic
Abstract 63. Sexual Dysfunction in Protease Inhibitor Recipients
Abstract 64. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Are Protective against the In Vitro Cytotoxicity of Adefovir (ADV) Mediated by the Human Renal Organic Anion Transporter 1 (hOAT1)
Abstract 65. Changes in Regional Fat Distribution in HIV-Infected Children
Abstract 66. Blood Lipid Levels and Body Composition in HIV-Infected Children Treated with Protease Inhibitors
Abstract 67. Is Lactic Acid a Predictor of Mitochondrial Dysfunction in ARV-Exposed Noninfected Infants?
Abstract 68. Assessing the Teratogenic Potential of Antiretroviral Drugs: Data from the Antiretroviral Pregnancy Registry
Abstract 69. Adherence and Viral Load in HIV-Infected Drug Users: Comparison of Self-Report and Medication Event Monitors (MEMS)
Abstract 70. Provider Estimate and Structured Patient Report of Adherence Compared with Unannounced Pill Count
Abstract 71. Impact of Directly Observed Therapy on Outcomes in HIV Clinical Trials
Abstract 72. Predictors of Adherence with Triple Combination Antiretroviral Therapy
Abstract 73. Nonadherence to Triple Combination Therapy Is Predictive of AIDS Progression and Death in HIV-Positive Men and Women
Abstract 74. Application and Outcome of Two Strategies to Increase HIV Medication Adherence: Life-Steps and Medication Monitoring
Abstract 76. Effect of Simultaneous or Staggered Dosing of Saquinavir (SQV), Ritonavir (RTV), and Nelfinavir (NFV) on Pharmacokinetic (PK) Interactions
Abstract 77. Pharmacokinetic (PK) Drug-Interaction between Amprenavir (APV) and Ritonavir (RTV) in HIV-Seronegative Subjects after Multiple, Oral Dosing
Abstract 78. The Addition of a Second Protease Inhibitor Eliminates Amprenavir-Efavirenz Drug Interactions and Increases Plasma Amprenavir Concentrations
Abstract 79. Pharmacokinetics of the Triple Combination of Saquinavir, Ritonavir, and Efavirenz in HIV-Positive Patients
Abstract 80. DONUT: The Pharmacokinetics (PK) of Once Daily Nevirapine (NVP) and Efavirenz (EFV) When Used in Combination
Abstract 81. The Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors when Coadministered with the HIV Protease Inhibitor Tipranavir in HIV-1 Infected Patients
Abstract 82. Pilot Study of BID and TID Combinations of Saquinavir-SGC (S), Delavirdine (D), Zidovudine (ZDV) & Lamivudine (3TC) as Initial Therapy: Pharmacokinetic (PK) Interaction between S-SGC and D
Abstract 83. Pharmacokinetic (PK) Interaction of AG1549, a Novel Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), with Protease Inhibitors (PI)
Abstract 84. Evaluation of Potential Pharmacokinetic Interactions between Emivirine + Combivir or Indinavir following Steady-State Administration in Healthy Male and Female Volunteers
Abstract 85. Abacavir (ABC) and Efavirenz (EFV) Pharmacokinetics (PK) in Adefovir (ADV)-Containing Salvage Regimens
Abstract 86. Pharmacokinetics of Adefovir Dipivoxil (ADV) in Combination with Saquinavir (SQV), Indinavir (IDV), Efavirenz (EFV), Delavirdine (DLV), Didanosine (ddI), or Lamivudine (3TC) in Normal Volunteers
Abstract 87. Pharmacokinetic (PK) and Pharmacodynamic (PD) Interactions between Nelfinavir and Methadone
Abstract 88. Managing Methadone and Non-Nucleoside Reverse Transcriptase Inhibitors: Guidelines for Clinical Practice
Abstract 89. Nevirapine (VIRAMUNE, NVP) and Ethinyl Estradiol/Norethindrone [ORTHO-NOVUM 1/35 (21 Pack) EE/NET] Interaction Study in HIV-1 Infected-Women
Abstract 90. Steady-State Pharmacokinetic Interaction of Modified-Dose Indinavir and Rifabutin
Abstract 91. A Pharmacokinetic (PK) Study of Intermittent Rifabutin (RB) Dosing with a Combination of Ritonavir (RT) and Saquinavir (SQ) in HIV Patients
Abstract 92. Mefloquine Decreases Ritonavir Exposure in Healthy Volunteers
Abstract 93. Cellular Influx/Efflux of Protease Inhibitors In Vitro
Abstract 94. A Relationship between Intracellular Zidovudine (ZDV-TP) and Lamivudine Triphosphate (3TC-TP) Concetrations in HIV-Infected Subjects
Abstract 95. Changes in Intracellular Deoxynucleotide (dATP) in Patients Treated with Hydroxyurea (HU) Alone and in Combination with Dideoxyinosine (ddI)
Abstract 96. Plasma and Intracellular Triphosphate (NRTI-TP) Concentrations of ZDV, D4T, and 3TC in Patients with HIV-Infection
Abstract 97. Effect of Stavudine and Zidovudine on Expression of the P-Glycoprotein Drug Transporter in HIV-1-Infected Patients
Abstract 98. The Bioequivalence of a Fixed Dose Triple NRTI Combination Tablet Containing Abacavir, Lamivudine, and Zidovudine
Abstract 99. Pharmacokinetics of a Second-Generation NNRTI, DPC 083, after Multiple Oral Doses in Healthy Volunteers
Abstract 100. Incorporation of Indinavir in Anti-HLA-DR Immunoliposomes to Target HIV Reservoirs
Abstract 101. Quantitation and Anti-Viral Effect of Unbound Plasma Indinavir (IDV) in HIV-Infected Persons
Abstract 102. Pharmacokinetics of a Second-Generation NNRTI, DPC 961, after Multiple Oral Doses in Healthy Volunteers
Abstract 103. Preliminary Assessments of the Pharmacokinetics of DAPD and Its Active Metabolite DXG in HIV-Infected Subjects
Abstract 104. Therapeutic Drug Monitoring (TDM) of Protease Inhibitors (PIs): What to Measure and When
Abstract 105. The Importance of Intergrating Virologic Information in Pharmacodynamic (PD) Analyses
Abstract 106. Mucosal Immunity Induced by Proviral DNA Vaccination and Its Effect on SIV Challenge
Abstract 107. Analysis of Mucosal Immunity to HIV-1 gag Enhanced by gag-Expressing DNA in Mice
Abstract 108. Induction of Anti-HIV Humoral and Cell-Mediated Immune Responses by Mucosal Immunizations Using Adjuvants and Virus-Like Particles
Abstract 109. Mucosal Antibody Responses in HIV-1-Infected Individuals: Dominance of Anti-gp160 IgG Responses in Comparison to IgA
Abstract 110. Mucosal Antibody Responses in HIV-Infected Individuals: Antibody-Secreting Cells in Peripheral Blood
Abstract 111. Mucosal Antibody Responses in HIV-Infected Individuals. Isotype Variations in Seven External Secretions
Abstract 112. Comparison of Mucosal Immune Responses with Viral Load in the Semen of HIV-1-Infected Men
Abstract 113. Transient Early Post-Inoculation Antiretroviral Treatment Facilitates Development of SIV-Specific Cellular Immune Responses, Sustained Modulation of Viral Replication and Reversal of CD4+ T Cell Depletion from GALT in SIV-Infected Rhesus Macaques
Abstract 114. HIV-1 Shedding Pattern in Semen Correlates with the Compartmentalization of Viral Quasispecies between Blood and Semen
Abstract 115. Sites of Productive Infection of HIV in the Male GU Tract
Abstract 116. HIV Infection Is Associated with Significant Mucosal Inflammation
Abstract 117. Chronic Inflammation with Increased HIV RNA Expression in the Vaginal Mucosa: Association with Heterosexual Transmission of HIV
Abstract 118. Identification of Target Cells in the Cervicovaginal Mucosa 18 Hours after SIV Inoculation
Abstract 119. Estrogen Protects against Vaginal Transmission of SIV
Abstract 120. Effect of HIV-1 on Lymphocyte Proliferation and Apoptosis in Gut-Associated Lymphoid Tissue
Abstract 121. Comparative Analysis of Lymphocytes Isolated from Peripheral Blood and Intestinal Mucosa of HIV-2-Infected Pig-Tailed Macaques
Abstract 122. Genetic Adaptation of HIV-1 for Intestinal Cells
Abstract 123. Effect of Recent Thymic Emigrants on HIV-1 Disease Progression
Abstract 124. Quantifying Recent Thymic Emigrants (RTE) in Blood and Tonsils of HIV-1-Infected Patients before and after HAART with a Real-Time PCR Assay for T-Cell Receptor Excisional Circles (TREC)
Abstract 125. Naive T Cell Division Affects the TREC Content of the Naive T Cell Population: No Evidence for Thymic Dysfunction in HIV-1 Infection
Abstract 126. Effect of HIV on Thymic Function before and after Antiretroviral Therapy in Children
Abstract 127. Analysis of Thymic Output during SIV/SHIV Infection
Abstract 128. Normal T Cell Turnover Rate in Sooty mangabeys Harboring Active Simian Immunodeficiency Virus Infection
Abstract 129. T Cell Division in HIV-1 Infection Is Mainly Caused By Immune Activation: A Longitudinal Analysis in Patients before and during HAART
Abstract 130. Cells Productively Infected by HIV Display Diminished Spontaneous Apoptosis but Enhanced Induced Apoptosis
Abstract 131. Markers of Lymphocyte Homing Distinguish CD4 T cells That Turnover in Response to HIV-1 Infection and Define Cells Regenerating at 1 Year
Abstract 132. Rapid Turnover of Bone Marrow in Both HIV-1-Infected and Uninfected Individuals
Abstract 133. HIV-1 Inhibition of Hematopoiesis In Vivo
Abstract 134. Influence of Follicular Dendritic Cells on Decay of Human Immunodeficiency Virus Type 1 during Antiretroviral Therapy
Abstract 135. Mathematical Model for the Decay of the Replication-Competent Latent Reservoir: Effect of Treatment Interruptions and IL-2 Stimulation
Abstract 136. HIV-1 Latent Reservoirs Renewed by Viral Replication in Activated CD4+ T Lymphocytes, Monocytes, and Resting CD4+ T Lymphocytes in Patients Receiving Potent Therapy
Abstract 137. Biphasic Decay of Latent HIV-1 in Resting CD4+ T Cells in Acute Seroconverters
Abstract 138. Analysis of the Evolution of HIV-1 pol Sequences in Latent HIV-1 Present in Resting CD4+ T-Lymphocytes in HIV-1 Infected Children Treated with HAART
Abstract 139. Detection of Circular Viral DNA in PBMC of HIV-Infected Individuals with No Detectable Viral RNA
Abstract 140. Persistent vRNA in PBMC from HIV-Infected Patients on Potent Antiretroviral Therapy Is Associated with Rare vRNA+ Cells
Abstract 141. Establishment of a SHIV/Macaque Model Using an R5-Tropic HIV-1 Subtype C Envelope
Abstract 142. Characterization of the Envelope Glycoproteins of a Pathogenic SHIV-HXBc2P3.2
Abstract 143. Evidence for Positive Selection Driving the Evolution of the HIV-1 Envelope Gene under Potent Antiviral Therapy
Abstract 144. Natural History of HIV-1 Infection in Chronic Infected Antiretroviral Naive Patients with Plasma Viral Load <5000 c/ml and CD4+ T Lymphocytes >500/mm3: Virologic and Immunologic Predictors of Progression
Abstract 145. A Highly Unique HIV-1-Infected Long-Term Nonprogressor: Insights into the Biology of Long-Term Nonprogression
Abstract 146. Low HIV-2 Plasma Viral Load Is Independent of Proviral Load and Correlated with Slow Disease Progression
Abstract 147. Predominance of Defective Human Immunodeficiency Virus Type-1 (HIV-1) in Individuals with a Low Plasma Viral Load
Abstract 148. Temporal Analysis of CD4+ T Cell Genome Expression during HIV-1 Infection
Abstract 149. Large-Scale Analysis of Gene Expression Affected by HIV-1 Infection Using cDNA Microarrays
Abstract 150. Genetic Changes That Can Compensate for the Loss of the Nef Gene
Abstract 151. Effects of Exogenous Nef on Uninfected (Bystander) Macrophages
Abstract 152. Monocyte Trafficking and HIV Disease Progression
Abstract 153. Nerve Growth Factor Is Essential for the Survival of HIV-Infected Macrophages
Abstract 154. Human Immunodeficiency Virus Infection of Human Placental Cord Blood CD34+AC133+ Stem Cells and Their Progeny
Abstract 155. Protease Inhibitor-Resistant HIV-1 Strains Isolated from Periods of Continued CD4+ T-Cell Accumulation Are Pathogenic in Human Lymphoid Histocultures
Abstract 156. Decreased HIV-1 Fitness after Long-Term Virologic Failure of Protease Inhibitor-Based Therapy: Relationship to Immunologic Response
Abstract 157. Eradication of Helminthic Infection Decreases HIV Plasma Viral Load in Dually Infected People
Abstract 158. HIV-1 Directly Kills Infected Cells through Disruption of Mitochondria and Activates Caspase 9-Induced Apoptosis
Abstract 159. Nonlytic Suppressive Activity against Different Biological Variants of HIV-1 by CD8+ T Lymphocytes from Exposed Uninfected Individuals
Abstract 160. Full-Length HIV-1 RNA Genomic Sequences from Frequently Exposed Kenyan Women: Extensive Recombination among Clades A, C, and D
Abstract 161. The Kidney Is a Previously Unrecognized Reservoir for HIV-1 Replication
Abstract 162. Aberrant Methylation of CDKN2A Gene in Human T-Cell Leukemia Virus Type 1-Associated Adult T-Cell Leukemia Cells
Abstract 163. Effects of Human T-Cell Leukemia Virus Type I (HTLV-I) Tax on Cellular p53, Using a Transgenic Mouse Model
Abstract 164. HIV Databases and Analysis Projects at Los Alamos: An Overview
Abstract 165. HIV-1 Subtype and Recombinant Nomenclature Proposal
Abstract 166. Identification of a New HIV-2 Subtype Based on Phylogenetic Analysis of Full-Length Genomic Sequence
Abstract 167. HIV-1 Subtype C: Characterization of Variants from Different Geographic Regions and Codon Usage Optimization for High-Level Expression In vivo
Abstract 168. Identification and Molecular Characterization of a New Primate Lentivirus (SIVcol) from Colobus Monkeys in Cameroon
Abstract 169. A Noninvasive Approach to Detect SIVcpz Infection in Wild Chimpanzees
Abstract 170. Genetic Characterization of HIV-1 Strains in an Immigrant Population Living in New York City
Abstract 171. Detection of Large Numbers of HIV-1 Group M Non-B Subtypes in New York City
Abstract 172. Divergence among HIV-1 Subtype B Viruses in the United States, 1998-1999
Abstract 173. The Impact of HIV-1 Genetic Diversity in Maryland: Under Quantifying "Non-B" Subtype HIV-1 Viral Loads with the FDA approved Assay
Abstract 174. HIV Non-B subtypes in a Large North American Cohort: Prevalence and Response to Antiretroviral Therapy
Abstract 175. Recombinant HIV-1 Variants Circulating in Spain
Abstract 176. A B/F Intersubtype-Recombinant HIV-1 Strain with Recombination in Pol Is Widely Circulating in Buenos Aires, Argentina
Abstract 177. Multiple HIV-1 Subtypes Circulating in Australia
Abstract 178. Molecular Characterization of a Growing HIV-1 Epidemic among IDUs in Eastern Europe
Abstract 179. Cross-Border Spread of Closely Related HIV-1 Subtype E Variant among Injecting Drug Users (IDUs) in Chino-Vietnam Boundary
Abstract 180. An Emerging HIV Epidemic among Injecting Drug Users in Guangxi Provice, Southern China
Abstract 181. Perinatal Transmission of Major, Minor, and Multiple HIV-1 Strains In Utero and Intrapartum
Abstract 182. T Lymphocyte Maturation Abnormalities in Vertically HIV-Exposed Uninfected Children
Abstract 183. Inhibition of and Selection against Vertical HIV-1 Transmission by the Placenta
Abstract 184. HIV-1 Viral Nucleic Acid Levels in the Female Genital Tract: Impact of the Menstrual Cycle and Implications for Transmission
Abstract 185. The Role of CD4+ T Cell Help and CD40 Ligand in the Expansion of HIV-Specific Memory Cytotoxic CD8+ T Cell Responses
Abstract 186. HIV-Specific CD4+ T Cells Are Maintained in Untreated Patients with or without Proliferative Responses to HIV Antigens
Abstract 187. The Number of HIV-Specific CD8+ T Cells after Stopping HAART Is Directly Correlated to Viral Load
Abstract 188. Correlation between Thymic Mass and TRECs in Age-Matched HIV-1-Infected People
Abstract 189. Phenotypic and Lymphokine Profile of the Effector Cells Associated with CD8+ Anti-HIV-1 Suppressor Activity (CASA)
Abstract 190. HLA DR-1 Tetramers Delineate HIV-1-Specific CD3+ CD4+ Cells
Abstract 191. Spatial Relationship between Virus-Producing Cells and CD8+ Cells, and Gag-Specific Precursor CTL Frequencies in Lymph Nodes of HIV-Infected Persons
Abstract 192. Molecular Evolution of HIV-1 Envelope-Specific Immunoglobulins: Single Germinal Center Analyses
Abstract 193. Viral Load and Risk of Heterosexual Transmission of HIV-1 among Sexual Partners
Abstract 194. Virologic Determinants of Heterosexual Transmission in Africa
Abstract 195. Do Gender Differences in Viral Load Predict Differences in HIV Disease Progression?
Abstract 196. Post-Exposure Prophylaxis after Sexual or Drug Use Exposure to HIV: Final Results from the San Francisco Post-Exposure Prevention (PEP) Project
Abstract 197. Who Is the Source of HIV Exposure in the San Francisco Post-Exposure Prevention (PEP) Project?
Abstract 198. Are At-Risk Populations Less Concerned about HIV Infection in the HAART Era?
Abstract 199. Mapping the Migration of HIV-1 among IDUs with Documented Seroconversion Dates in Western European Countries by Ccombining Phylogenetic and Epidemiological Data
Abstract 200. Patterns of Plasma HIV-1 RNA Levels after Failure of T-Cell Homeostasis
Abstract 201. The Australian Prevalence Survey of Lipodystrophy Syndrome
Abstract 202. Altered Fat Distribution in Men on Reverse Transcriptase Inhibitors (RTIs)
Abstract 203. Lipid Alterations in HIV-Infected Men with Lipodystrophy Are Correlated with Increase in Cortisol/DHEA Ratio and in Serum Interferon Alpha
Abstract 204. Hyperinsulinemia, Central Adiposity, and Reduced Heparin-Releasable LPL Activity in HIV+ PI-Associated Hypertriglyceridemia
Abstract 205. A Randomized, Multicenter Study of Protease Inhibitor (PI) Substitution in Aviremic Patients with Antiretroviral (ARV) Lipodystrophy Syndrome
Abstract 206. Clinical, Virological, and Immunological Benefit of Switching the Protease Inhibitor (PI) by Nevirapine (NVP) in HAART-Experienced Patients Suffering Lipodystrophy (LD): 36-Week Follow-Up
Abstract 207. Accelerated Bone Mineral Loss in HIV-Infected Patients Receiving Potent Antiretroviral Therapy
Abstract 208. Osteopenia in a Randomized, Multicenter Study of Protease Inhibitor (PI) Substitution in Patients with the Lipodystrophy Syndrome and Well-Controlled HIV Viremia
L1 Our Retroviral Heritage
L2 The State of HIV Vaccine Research
S1 HIV cDNA Integration: Mechanism and Design of Inhibitors
S2 Inhibitors of HIV Integrase: Antiviral Activity and Mechanism
S3 Reverse Transcriptase-Associated Ribonuclease H Activity as a Therapeutic Target
S4 Humanized DNA Sequences for HIV Vaccine Development
S5 Vaccine-Elicited SIV-Specific Immunity: CTL and Protection
S6 Therapeutic Use of a Recombinant Attenuated Pox Virus Vaccine in SIV-Infected Macaques
S7 Clinical Trials of Candidate HIV-1 Vaccines: Challenges and Opportunities
S8 Epidemiology and Natural History of Hepatitis C
S9 Molecular Virology of Hepatitis C: An Overview
S10 The Immunopathogenesis of Hepatitis C Virus
S11 The Treatment of Chronic HCV Infection in HIV-Infected Persons
© 7th Conference on Retroviruses and Opportunistic Infections, Foundation for Retrovirology and Human Health
